Moshe Talpaz

Moshe Talpaz

UNVERIFIED PROFILE

Are you Moshe Talpaz?   Register this Author

Register author
Moshe Talpaz

Moshe Talpaz

Publications by authors named "Moshe Talpaz"

Are you Moshe Talpaz?   Register this Author

100Publications

2455Reads

10Profile Views

SOHO State of the Art Updates and Next Questions: Myelofibrosis.

Clin Lymphoma Myeloma Leuk 2019 Apr 22;19(4):191-199. Epub 2019 Mar 22.

University of Michigan Rogel Cancer Center, Ann Arbor, MI.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650193017
Publisher Site
http://dx.doi.org/10.1016/j.clml.2019.03.011DOI Listing
April 2019

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.

J Hematol Oncol 2018 Aug 7;11(1):101. Epub 2018 Aug 7.

University of Maryland, Greenebaum Comprehensive Cancer Center, 22 S. Greene St, Baltimore, MD, 21201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-018-0642-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081850PMC
August 2018

The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia.

Leuk Res 2018 07 1;70:91-96. Epub 2018 Jun 1.

Department of Pharmacy Services and Clinical Sciences, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.05.011DOI Listing
July 2018

Primary myelofibrosis evolving to an aplastic appearing marrow.

Clin Case Rep 2018 Jul 31;6(7):1393-1395. Epub 2018 May 31.

Division of Hematology/Oncology Department of Internal Medicine University of Michigan Ann Arbor MI USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.1618DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028358PMC
July 2018

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.

Clin Lymphoma Myeloma Leuk 2018 05 2;18(5):e201-e210. Epub 2018 Mar 2.

University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.02.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927833PMC
May 2018

Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.

Ann Hematol 2018 Apr 29;97(4):573-584. Epub 2017 Dec 29.

Department of Pharmacy Services and Clinical Sciences, Michigan Medicine and University of Michigan College of Pharmacy, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-017-3217-1
Publisher Site
http://dx.doi.org/10.1007/s00277-017-3217-1DOI Listing
April 2018

Dasatinib dose management for the treatment of chronic myeloid leukemia.

Cancer 2018 Apr 25;124(8):1660-1672. Epub 2018 Jan 25.

Department of Hematology and Oncology, Versailles Medical Center, INSERM UMR 1173, University of Versailles Saint-Quenti-en-Yvelines, Paris Saclay, Le Chesnay, France.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31232
Publisher Site
http://dx.doi.org/10.1002/cncr.31232DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901015PMC
April 2018

Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth.

Neoplasia 2018 02 14;20(2):152-164. Epub 2017 Dec 14.

Department of Internal Medicine/Division of Hematology/Oncology, University of Michigan School of Medicine and Comprehensive Cancer Center. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2017.11.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735260PMC
February 2018

Induction of p53 suppresses chronic myeloid leukemia.

Leuk Lymphoma 2017 09 13;58(9):1-14. Epub 2017 Jan 13.

a Comprehensive Cancer Center , University of Michigan , Ann Arbor , MI , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1272682DOI Listing
September 2017

New Series: SOHO 'State of the Art Updates and Next Questions'.

Clin Lymphoma Myeloma Leuk 2017 08;17(8):463

Chair, Scientific Committee, Society of Hematologic Oncology; and, Alexander J. Trotman Professor of Leukemia Research, Associate Director for Translational Research, Associate Chief of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.06.036DOI Listing
August 2017

Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis.

Am J Hematol 2017 Jun 2;92(6):555-561. Epub 2017 May 2.

Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24728DOI Listing
June 2017

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.

Leuk Lymphoma 2016 10 27;57(10):2259-67. Epub 2016 Jul 27.

c MRC Weatherall Institute of Molecular Medicine and NIHR Biomedical Research Centre , University of Oxford , Oxford , UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1195501DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975083PMC
October 2016

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients.

Leuk Res 2016 09 22;48:84-91. Epub 2016 Jul 22.

ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA, 02139-4234, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.07.007DOI Listing
September 2016

A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis.

Tomography 2016 Mar;2(1):67-78

Center for Molecular Imaging, Department of Radiology, University of Michigan, Ann Arbor, MI, USA; Department of Biological Chemistry, University of Michigan, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18383/j.tom.2016.00115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872873PMC
March 2016

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Blood 2016 Feb 24;127(6):703-12. Epub 2015 Nov 24.

Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-08-660977DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760131PMC
February 2016

Ruxolitinib for the treatment of patients with polycythemia vera.

Expert Rev Hematol 2015 Aug 17;8(4):391-401. Epub 2015 May 17.

Hôpital Saint-Louis and Université Paris Diderot, Paris, France.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/17474086.2015.10
Publisher Site
http://dx.doi.org/10.1586/17474086.2015.1045869DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627585PMC
August 2015

Meir Wetzler, MD.

Cancer 2015 Jul 1;121(13):2106-7. Epub 2015 Apr 1.

Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.29391
Publisher Site
http://dx.doi.org/10.1002/cncr.29391DOI Listing
July 2015

CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis.

Mol Cancer Ther 2015 Jul 12;14(7):1717-27. Epub 2015 May 12.

Cellular and Molecular Biology Graduate Program, University of Michigan, Ann Arbor, Michigan. Department of Internal Medicine Division Hematology-Oncology, University of Michigan, Ann Arbor, Michigan. Department of Obstetrics-Gynecology, Division of Gynecologic Oncology, University of Michigan, Ann Arbor, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-0607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496272PMC
July 2015

The interferon-alpha revival in CML.

Ann Hematol 2015 Apr 27;94 Suppl 2:S195-207. Epub 2015 Mar 27.

Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, Comprehensive Cancer Center Room 4302, Ann Arbor, MI, 48109-5936, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-015-2326-y
Publisher Site
http://dx.doi.org/10.1007/s00277-015-2326-yDOI Listing
April 2015

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

J Natl Compr Canc Netw 2015 Apr;13(4):424-34

From Northwestern University Feinberg School of Medicine, Chicago, Illinois; Stanford Cancer Institute, Stanford University, Stanford, California; Duke Cancer Institute, Duke University, Durham, North Carolina; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; University of California, San Francisco, San Francisco, California; Johns Hopkins University School of Medicine, Baltimore, Maryland; Moores Cancer Center, UC San Diego, San Diego, California; University of Colorado Cancer Center, Aurora, Colorado; Fred Hutchinson Cancer Research Center, Seattle, Washington; Dana Farber Cancer Institute, Boston, Massachusetts; Memorial Sloan Kettering Cancer Center, New York; New York; Moffitt Cancer Center and Research Institute, Tampa, Florida; The Ohio State University, Columbus, Ohio; Fred & Pamela Buffett Cancer Center, Omaha, Nebraska; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Roswell Park Cancer Institute, Buffalo, New York; Washington University-Siteman Cancer Center, St Louis, Missouri; St. Jude Children's Research Hospital, Memphis, Tennessee; University of Alabama at Birmingham, Birmingham, Alabama; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee; Yale University School of Medicine; New Haven, Connecticut; University of Utah, Salt Lake City, Utah; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; City of Hope Cancer Center, Los Angeles, California; The University of Texas MD Anderson Cancer Center, Houston, Texas; and Mayo Clinic Cancer Center, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
April 2015

Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway.

Oncotarget 2014 Jul;5(14):5559-69

Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170643PMC
http://dx.doi.org/10.18632/oncotarget.2140DOI Listing
July 2014

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.

Proc Natl Acad Sci U S A 2014 Mar 18;111(9):3550-5. Epub 2014 Feb 18.

Department of Thoracic, Head/Neck Medical Oncology and Department of Molecular and Cellular Oncology, MD Anderson Cancer Center, Houston, TX 77030.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1321173111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948238PMC
March 2014

Ponatinib in Philadelphia chromosome-positive leukemias.

N Engl J Med 2014 02;370(6):577

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1315234DOI Listing
February 2014

Hematology clinic: chronic myelogenous leukemia.

Hematology 2013 Nov;18(6):372-3

University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1179/1024533213Z.000000000242DOI Listing
November 2013

Sequential therapy in chronic myelogenous leukemia: where do emerging therapies fit within current treatment regimens?

Clin Adv Hematol Oncol 2013 Nov;11(11 Suppl 17):1-15

Weill Cornell Medical College /New York Presbyterian Hospital, New York, New York.

View Article

Download full-text PDF

Source
November 2013

A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination.

Cell Signal 2011 Dec 9;23(12):2076-85. Epub 2011 Aug 9.

Department of Internal Medicine, Division of Hematology-Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellsig.2011.08.002DOI Listing
December 2011

Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma.

Bioorg Med Chem 2011 Dec 7;19(23):7194-204. Epub 2011 Oct 7.

Department of Experimental Therapeutics, M D Anderson Cancer Center, Houston, TX 77030, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2011.09.057DOI Listing
December 2011

Managing resistance in chronic myeloid leukemia.

Blood Rev 2011 Nov 6;25(6):279-90. Epub 2011 Oct 6.

Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2011.09.001DOI Listing
November 2011

Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity.

Biochem Pharmacol 2011 Aug 19;82(4):341-9. Epub 2011 May 19.

Department of Internal Medicine, Division of Hematology-Oncology, University of Michigan, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2011.05.012DOI Listing
August 2011

Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis.

Blood 2011 Mar 19;117(11):3151-62. Epub 2011 Jan 19.

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-03-276477DOI Listing
March 2011

Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia.

Blood 2010 Dec 20;116(23):4958-67. Epub 2010 Aug 20.

Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-0936, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-01-266999DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012590PMC
December 2010

Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.

Cancer Res 2010 Nov 2;70(22):9265-76. Epub 2010 Nov 2.

Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-1530DOI Listing
November 2010

PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.

PLoS One 2010 Jul 26;5(7):e11770. Epub 2010 Jul 26.

Section of Transplant Immunology, Department of Blood and Marrow Transplantation, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0011770PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909896PMC
July 2010

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.

Biochem Pharmacol 2010 Mar 27;79(5):688-97. Epub 2009 Oct 27.

University of Michigan, Department of Internal Medicine, 1500 E. Medical Center Dr., Room CC4306, Ann Arbor, MI 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2009.10.009DOI Listing
March 2010

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.

Hematology Am Soc Hematol Educ Program 2009 :461-76

Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2009.1.461DOI Listing
March 2010

Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.

J Clin Oncol 2009 Oct 8;27(30):5015-22. Epub 2009 Sep 8.

Comprehensive Cancer Center, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109-5936, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.19.5370DOI Listing
October 2009

Following the hedgehog to new cancer therapies.

N Engl J Med 2009 Sep 2;361(12):1202-5. Epub 2009 Sep 2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe0906092DOI Listing
September 2009

Getting to the stem of chronic myeloid leukaemia.

Nat Rev Cancer 2008 May;8(5):341-50

University of Michigan, Internal Medicine-Hematology Oncology, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109-45936, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc2368DOI Listing
May 2008

The fine tuning of therapy for chronic myeloid leukemia and upcoming challenges.

Authors:
Moshe Talpaz

Clin Lymphoma Myeloma 2008 Mar;8 Suppl 3:S74

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLM.2008.s.001DOI Listing
March 2008

Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors.

Clin Lymphoma Myeloma 2008 Mar;8 Suppl 3:S95-S106

Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLM.2008.s.005DOI Listing
March 2008

The role of interferon-alpha in the treatment of chronic myeloid leukemia.

Cytokine Growth Factor Rev 2007 Oct-Dec;18(5-6):459-71. Epub 2007 Aug 20.

Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13596101070008
Publisher Site
http://dx.doi.org/10.1016/j.cytogfr.2007.06.015DOI Listing
January 2008

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

Leuk Lymphoma 2007 Dec;48(12):2310-22

Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109-0843, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1080/1042819070166598
Publisher Site
http://dx.doi.org/10.1080/10428190701665988DOI Listing
December 2007

Degrasyn activates proteasomal-dependent degradation of c-Myc.

Cancer Res 2007 Apr;67(8):3912-8

Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-4464DOI Listing
April 2007